Roche teams up with research institutions for new Alzheimer’s trial Reuters Mar 4, 2022 The trial aims to evaluate the potential of gantenerumab to slow disease progression in people with the earliest biological signs…
US FDA grants breakthrough therapy designation to Roche’s anti-amyloid beta antibody gantenerumab EP News Bureau Oct 11, 2021 Gantenerumab is an investigational antibody in phase-III development for early Alzheimer's disease (AD)
